Telus Investors Weigh SIM Fee Against Soaring Debt and Stalled Dividend Growth
13.06.2026 - 01:11:32 | boerse-global.de
Telus introduced a C$15 charge for SIM cards on Friday, replacing the old C$80 activation fee that was banned by regulators. The new levy applies to all physical and eSIM purchases outside the company’s website, showing up directly on the first bill. Management says the change is meant to bring greater transparency to customer invoices, while also salvaging some of the lost connection revenue in Canada’s fiercely competitive wireless market. Investors have so far shrugged off the shift — the stock traded at C$16.75, up slightly on the day, though still down roughly 7% year to date and hovering near its 52-week low of C$16.18.
Shareholders expecting a steady income stream will receive a quarterly dividend of C$0.4184 per share (equivalent to US$0.312), payable on July 2 to holders of record as of June 10. That translates into a juicy headline yield in a yield-starved environment. But the board has frozen dividend growth and also trimmed the discount on the reinvestment plan — moves that signal a fundamental shift in priorities after years of rewarding income?focused investors.
The reason for the pause becomes clear when looking at the balance sheet. Telus ended the first quarter with net debt to EBITDA at 3.5 times, a level that aggressively constrains financial flexibility. The company wants to bring that ratio down to 3.3x by the end of 2026 and eventually to 3.0x a year later. That deleveraging imperative comes at the expense of dividend increases.
Should investors sell immediately? Or is it worth buying Telus?
Operationally, Telus Health remains the wild card. The division, which reaches more than 160 million people globally and generated C$1.5 billion in operating revenue through the third quarter of 2025, has hired TD Securities and Jefferies to explore monetisation options. Analysts see a partial sale or spin?off as more likely than a clean outright sale. The market will be watching closely — a drawn?out, fragmented process could do little for the share price, whereas a simple transaction would slash debt.
There are some genuine positives on the cash flow front. Free cash flow jumped 19% in the first quarter to C$583 million, and management confirmed a full?year target of roughly C$2.45 billion, representing 10% growth. On paper, that covers the dividend. Yet the same filing warns that there is no guarantee dividend growth will resume. The caution is worth noting, especially after net profit collapsed 52% to C$144 million in the same period.
Technically, the stock remains in a clear downtrend. The relative strength index stands at 35.8, not yet oversold, and no bottoming pattern has formed. The dividend yield is real, but it comes from a company whose earnings are sliding and whose dividend growth is on hold. Until Telus Health delivers a concrete catalyst to meaningfully lower leverage, the payout looks more like compensation for holding a structurally challenged stock than a reliable income engine.
Ad
Telus Stock: New Analysis - 13 June
Fresh Telus information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
